MYCR Stock Analysis: Mycronic publ | ST
Specialty Industrial Machinery | ST, Sweden | Market Cap: 69.946m SEK | 12M Return: 56.3% | SE0025158629 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 78.4M
EPS Trend: -13.3%
Qual. Beats: 0
Rev. Trend: 96.8%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Mycronic AB (publ) is a Swedish provider of production equipment for the global electronics industry, headquartered in Täby and incorporated in 1989 (formerly Micronic Mydata AB, renamed in June 2014). The company operates through four segments: Pattern Generators (mask writers and metrology systems for display and semiconductor manufacturing), PCB Assembly (flexible solutions including jet printing, stencil printing, 3D inspection, component placement, and automated storage), High-Volume (automated dispensing and conformal coating systems), and Global Technologies (die bonding, PCB test, photonic interconnects, magnetic test, and applied plasma).
Mycronic sells through agents and distributors, serving customers in aerospace, defense, medical, and industrial electronics across Sweden, Europe, the Americas, China, South Korea, and other parts of Asia. As a mid-cap player in the Electronic Equipment & Instruments sub-industry, the company benefits from a diversified business model spanning photomask production tools, SMT (surface-mount technology) assembly equipment, and specialized test and bonding systems used by electronics manufacturers worldwide.
- Display panel capex cycle drives Pattern Generator mask writer orders
- Advanced semiconductor packaging demand accelerates die bonding equipment sales
- China display spending recovery lifts Pattern Generators segment revenue
| Net Income: 1.74b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -3.03 > 1.0 |
| NWC/Revenue: 46.59% < 20% (prev 39.29%; Δ 7.30% < -1%) |
| CFO/TA 0.17 > 3% & CFO 2.05b > Net Income 1.74b |
| Net Debt (-1.93b) to EBITDA (2.67b): -0.72 < 3 |
| Current Ratio: 2.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.3m) vs 12m ago -0.18% < -2% |
| Gross Margin: 52.87% > 18% (prev 54.37%; Δ -1.49% > 0.5%) |
| Asset Turnover: 76.39% > 50% (prev 77.76%; Δ -1.37% > 0%) |
| Interest Coverage Ratio: 29.95 > 6 (EBIT TTM 2.31b / Interest Expense TTM 77.0m) |
| A: 0.33 (Total Current Assets 7.32b - Total Current Liabilities 3.29b) / Total Assets 12.3b |
| B: 0.45 (Retained Earnings 5.57b / Total Assets 12.3b) |
| C: 0.20 (EBIT TTM 2.31b / Avg Total Assets 11.3b) |
| D: 1.79 (Book Value of Equity 7.88b / Total Liabilities 4.41b) |
| Altman-Z'' = 6.87 = AAA |
| DSRI: 1.04 (Receivables 2.17b/1.94b, Revenue 8.65b/8.05b) |
| GMI: 1.03 (GM 54.37% / 52.87%) |
| AQI: 0.88 (AQ_t 0.33 / AQ_t-1 0.38) |
| SGI: 1.07 (Revenue 8.65b / 8.05b) |
| TATA: -0.03 (NI 1.74b - CFO 2.05b) / TA 12.3b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of October 09, 2026, the stock is trading at SEK 346.20 with a total of 151,433 shares traded. Over the past week, the price has changed by +0.64%, over one month by +8.46%, over three months by +21.30% and over the past year by +56.25%.
Current recommended Stop Loss: 327.50 (which is 5.4% or 1.8 ATR below the current price).
Mycronic publ has no consensus analysts rating.
P/E Trailing = 40.3378
P/E Forward = 18.0505
P/S = 8.0872
P/B = 8.4342
P/EG = 0.4163
Revenue TTM = 8.65b SEK
EBIT TTM = 2.31b SEK
EBITDA TTM = 2.67b SEK
Long Term Debt = 12.0m SEK (from longTermDebt, last fiscal year)
Short Term Debt = 135.0m SEK (from shortTermDebt, last quarter)
Debt = 756.0m SEK (from shortLongTermDebtTotal, last quarter) + Leases 336.0m
Net Debt = -1.93b SEK (calculated: Debt 756.0m - CCE 2.69b)
Enterprise Value = 68.0b SEK (69.9b + Debt 756.0m - CCE 2.69b)
Interest Coverage Ratio = 29.95 (Ebit TTM 2.31b / Interest Expense TTM 77.0m)
EV/FCF = 51.68x (Enterprise Value 68.0b / FCF TTM 1.32b)
FCF Yield = 1.93% (FCF TTM 1.32b / Enterprise Value 68.0b)
FCF Margin = 15.22% (FCF TTM 1.32b / Revenue TTM 8.65b)
Net Margin = 20.07% (Net Income TTM 1.74b / Revenue TTM 8.65b)
Gross Margin = 52.87% ((Revenue TTM 8.65b - Cost of Revenue TTM 4.08b) / Revenue TTM)
Gross Margin QoQ = 56.46% (prev 60.21%)
Tobins Q-Ratio = 5.53 (Enterprise Value 68.0b / Total Assets 12.3b)
Interest Expense / Debt = 10.19% (Interest Expense 77.0m / Debt 756.0m)
Taxrate = 21.89% (486.0m / 2.22b)
NOPAT = 1.80b (EBIT 2.31b * (1 - 21.89%))
Current Ratio = 2.22 (Total Current Assets 7.32b / Total Current Liabilities 3.29b)
Debt / Equity = 0.10 (Debt 756.0m / totalStockholderEquity, last quarter 7.88b)
Debt / EBITDA = -0.72 (Net Debt -1.93b / EBITDA 2.67b)
Debt / FCF = -1.47 (Net Debt -1.93b / FCF TTM 1.32b)
Total Stockholder Equity = 7.44b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.33% (Net Income 1.74b / Total Assets 12.3b)
RoE = 23.33% (Net Income TTM 1.74b / Total Stockholder Equity 7.44b)
RoCE = 30.94% (EBIT 2.31b / Capital Employed (Equity 7.44b + L.T.Debt 12.0m))
RoIC = 20.69% (NOPAT 1.80b / Invested Capital 8.71b)
WACC = 10.45% (E(69.9b)/V(70.7b) * Re(10.48%) + D(756.0m)/V(70.7b) * Rd(10.19%) * (1-Tc(0.22)))
Discount Rate = 10.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.00 | Cagr: 36.08%
[DCF] Terminal Value 67.17% ; FCFF base≈1.36b ; Y1≈1.28b ; Y5≈1.19b
[DCF] Fair Price = 81.15 (EV 13.9b - Net Debt -1.93b = Equity 15.8b / Shares 195.3m; r=10.45% [WACC]; 5y FCF grow -7.39% → 2.50% )
EPS Correlation: -13.32 | EPS CAGR: -3.84% | SUE: 0.56 | # QB: 0
Revenue Correlation: 96.84 | Revenue CAGR: 18.60% | SUE: 1.94 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.74 | Chg30d=-2.05% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=10.06 | Chg30d=-1.60% | Revisions=-25% | GrowthEPS=+25.9% | GrowthRev=+17.4%
EPS next Year (2027-12-31): EPS=11.01 | Chg30d=-0.02% | Revisions=-25% | GrowthEPS=+9.4% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: -50% (up=0, down=3)